Cargando…
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital....
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595088/ https://www.ncbi.nlm.nih.gov/pubmed/33116181 http://dx.doi.org/10.1038/s41598-020-75477-9 |
_version_ | 1783601781549301760 |
---|---|
author | Egaña, Larraitz Auzmendi-Iriarte, Jaione Andermatten, Joaquin Villanua, Jorge Ruiz, Irune Elua-Pinin, Alejandro Aldaz, Paula Querejeta, Arrate Sarasqueta, Cristina Zubia, Felix Matheu, Ander Samprón, Nicolas |
author_facet | Egaña, Larraitz Auzmendi-Iriarte, Jaione Andermatten, Joaquin Villanua, Jorge Ruiz, Irune Elua-Pinin, Alejandro Aldaz, Paula Querejeta, Arrate Sarasqueta, Cristina Zubia, Felix Matheu, Ander Samprón, Nicolas |
author_sort | Egaña, Larraitz |
collection | PubMed |
description | O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital. Surprisingly, methylation of MGMT promoter did not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. Specifically, overall survival (OS) and progression-free survival (PFS) did not differ significantly by MGMT methylation status in our cohort. In contrast, both were longer in patients who received treatment, received more TMZ cycles, had a better general status and perform at least a partial resection. No association was detected between methylation of MGMT promoter and molecular markers such as ATRX, IDH, p53 and Ki67. These results indicate that MGMT methylation did not influence in patient survival in our cohort. |
format | Online Article Text |
id | pubmed-7595088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75950882020-10-29 Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital Egaña, Larraitz Auzmendi-Iriarte, Jaione Andermatten, Joaquin Villanua, Jorge Ruiz, Irune Elua-Pinin, Alejandro Aldaz, Paula Querejeta, Arrate Sarasqueta, Cristina Zubia, Felix Matheu, Ander Samprón, Nicolas Sci Rep Article O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital. Surprisingly, methylation of MGMT promoter did not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. Specifically, overall survival (OS) and progression-free survival (PFS) did not differ significantly by MGMT methylation status in our cohort. In contrast, both were longer in patients who received treatment, received more TMZ cycles, had a better general status and perform at least a partial resection. No association was detected between methylation of MGMT promoter and molecular markers such as ATRX, IDH, p53 and Ki67. These results indicate that MGMT methylation did not influence in patient survival in our cohort. Nature Publishing Group UK 2020-10-28 /pmc/articles/PMC7595088/ /pubmed/33116181 http://dx.doi.org/10.1038/s41598-020-75477-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Egaña, Larraitz Auzmendi-Iriarte, Jaione Andermatten, Joaquin Villanua, Jorge Ruiz, Irune Elua-Pinin, Alejandro Aldaz, Paula Querejeta, Arrate Sarasqueta, Cristina Zubia, Felix Matheu, Ander Samprón, Nicolas Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital |
title | Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital |
title_full | Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital |
title_fullStr | Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital |
title_full_unstemmed | Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital |
title_short | Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital |
title_sort | methylation of mgmt promoter does not predict response to temozolomide in patients with glioblastoma in donostia hospital |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595088/ https://www.ncbi.nlm.nih.gov/pubmed/33116181 http://dx.doi.org/10.1038/s41598-020-75477-9 |
work_keys_str_mv | AT eganalarraitz methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT auzmendiiriartejaione methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT andermattenjoaquin methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT villanuajorge methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT ruizirune methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT eluapininalejandro methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT aldazpaula methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT querejetaarrate methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT sarasquetacristina methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT zubiafelix methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT matheuander methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital AT sampronnicolas methylationofmgmtpromoterdoesnotpredictresponsetotemozolomideinpatientswithglioblastomaindonostiahospital |